Core Insights - The application of AI in the healthcare sector is transitioning from "concept validation" to "industrial implementation," marking a critical turning point for companies like iFlytek Medical [1] - iFlytek Medical has won a bid worth 428 million yuan for a software service project under the National AI Application Pilot Base, indicating a significant shift in its role from a product supplier to an infrastructure builder in the industry [1] Group 1: Industry Trends - The National AI Application Pilot Base aims to address common challenges in deploying large models in vertical industries, such as unclear technical paths and lack of standards [3] - The project focuses on "grassroots health services," which is currently the most urgent area in the healthcare system, supported by strong policy backing [3] - iFlytek Medical's role as a core co-builder of future national standards for medical AI is emphasized through its involvement in this strategic infrastructure [3] Group 2: Technological Advancements - iFlytek Medical's commitment to "fully domestic computing power training and fully autonomous control" creates a high entry barrier, providing a competitive advantage in meeting the digital transformation needs of government and large medical institutions [5] - The company's medical large model has outperformed international mainstream models in key areas, demonstrating the feasibility of domestic large model technology routes and providing a solid foundation for long-term valuation [5] Group 3: Business Model Evolution - iFlytek Medical is evolving its business model from traditional software delivery to a comprehensive service model that includes "large models + data + operations" [7] - The core product "Smart Medical Assistant" has been implemented across 31 provinces, serving over 250,000 grassroots doctors and significantly improving the quality of medical services [7] - The project encompasses 21 application scenarios, directly addressing key management needs such as cost control and tiered diagnosis, which is expected to enhance user stickiness and generate sustainable service revenue [7] Group 4: Market Positioning - The participation in the national pilot base indicates that iFlytek Medical is entering a phase of performance realization, leveraging its national-level data assets and large model capabilities [8] - The company is poised to reshape the value coordinates of "AI + healthcare," with its long-term growth potential attracting significant market attention [8]

Core Insights - The application of AI in the healthcare sector is transitioning from "concept validation" to "industrial implementation," marking a critical turning point for companies like iFlytek Medical [1] - iFlytek Medical has won a bid worth 428 million yuan for a software service project under the National AI Application Pilot Base, indicating a shift from being a product supplier to an industry infrastructure builder [1] Group 1: Strategic Positioning - The National AI Application Pilot Base aims to address common challenges in the vertical industry, such as unclear technical paths and lack of standards, positioning itself as a strategic infrastructure for AI [2] - iFlytek Medical's role as a contractor signifies its elevation to a core co-builder of future national standards for medical AI [2] - The focus on "grassroots health services" reflects a high demand and strong policy support, allowing iFlytek Medical to create a replicable "medical AI operating system" [2] Group 2: Technological Advantages - In the current complex environment, supply chain security and technological autonomy are critical for evaluating hard-tech companies' core competitiveness [3] - iFlytek Medical's commitment to "fully domestic computing power training and fully autonomous control" creates a high entry barrier, providing a competitive advantage in digital transformation for government and large medical institutions [3] - The performance of iFlytek Medical's AI model has surpassed international benchmarks, validating the feasibility of domestic AI technology routes and supporting long-term valuation [3] Group 3: Business Model Evolution - iFlytek Medical is evolving its business model from traditional software delivery to a comprehensive service model that includes "large models + data + operations" [4] - The core product "Smart Medical Assistant" has been implemented across 31 provinces, serving over 250,000 grassroots doctors and significantly improving the quality of medical services [4] - The project encompasses 21 application scenarios, directly addressing key management needs such as cost control and tiered diagnosis, which is expected to enhance user engagement and generate sustainable service revenue [4] Group 4: Market Outlook - The integration of AI technology in healthcare is essential for bridging urban-rural medical gaps and enhancing service efficiency, positioning iFlytek Medical for significant performance realization [5] - As a platform company with national-level data assets and core model capabilities, iFlytek Medical is reshaping the value coordinates of "AI + healthcare," warranting high market attention for its long-term growth potential [5]

Core Viewpoint - The article highlights the recent increase in southbound capital holdings in iFlytek Medical Technology (02506.HK), indicating a positive trend in investor interest and potential growth in the company's stock performance [1]. Group 1: Southbound Capital Holdings - On November 19, southbound capital increased its holdings by 18,900 shares in iFlytek Medical Technology, marking a 0.50% increase [2]. - Over the past five trading days, there were four days of net increases, totaling 27,800 shares [1]. - In the last 20 trading days, there were 12 days of net increases, amounting to 102,100 shares [1]. - As of now, southbound capital holds 3,828,100 shares of iFlytek Medical Technology, which represents 4.94% of the company's total issued ordinary shares [1]. Group 2: Company Overview - iFlytek Medical Technology is primarily engaged in providing AI-enabled medical solutions in China [2]. - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [2]. - The grassroots medical services line consists of intelligent medical assistants and chronic disease management [2]. - The hospital services line includes smart hospital solutions and diagnostic assistants [2]. - Patient services encompass smart hospital patient services, post-discharge management, imaging cloud platforms, and medical devices [2]. - The regional management platform solutions line features smart health solutions and smart medical insurance [2].

Core Viewpoint - Southbound funds increased their holdings in iFlytek Medical Technology (02506.HK) by 650.0 shares on November 17, 2025, while experiencing a net reduction of 4,500.0 shares over the past five trading days [1][2]. Group 1: Southbound Fund Activity - In the last 20 trading days, iFlytek Medical Technology saw 12 days of net increases in southbound fund holdings, totaling 82,600 shares [1]. - As of November 17, 2025, southbound funds hold 3.7932 million shares of iFlytek Medical Technology, representing 4.9% of the company's total issued ordinary shares [1][2]. Group 2: Company Overview - iFlytek Medical Technology is primarily engaged in providing AI-powered medical solutions in China, with business lines including grassroots medical services, hospital services, patient services, and regional management platform solutions [2]. - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [2]. - Patient services encompass smart hospital patient services, post-discharge management, imaging cloud platforms, and medical devices [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 2025年11月10日舉行之臨時股東大會的表決結果 訊飛醫療科技股份有限公司（「本公司」）於2025年11月10日舉行之2025年第一次 臨時股東大會（「臨時股東大會」）上，所有列載於日期為2025年10月20日的臨時 股東大會通告內的決議案均以一股一票方式進行投票表決。 香港，2025年11月10日 截至本公告日期，本公司董事會包括：(i)執行董事陶曉東博士；(ii)非執行董事劉慶峰博士、 趙志偉先生及段大為先生；及(iii)獨立非執行董事汪揚教授、趙惠芳教授及談慶先生。 – 2 – 臨時股東大會的投票結果如下： | | 普通決議案 | 票數(%) | | | | --- ...

Core Viewpoint - The article discusses the recent developments and performance of Xunfei Healthcare, highlighting its growth trajectory and market positioning in the healthcare sector [1]. Group 1: Company Performance - Xunfei Healthcare has reported a significant increase in revenue, with a year-on-year growth of 25%, reaching a total of 1.5 billion [1]. - The company has expanded its service offerings, which has contributed to a 15% increase in customer acquisition [1]. - The net profit margin has improved to 12%, reflecting better operational efficiency and cost management [1]. Group 2: Market Trends - The healthcare industry is experiencing a shift towards digital health solutions, with a projected market growth rate of 20% annually [1]. - Increased investment in healthcare technology is driving innovation and competition among companies in the sector [1]. - Regulatory changes are expected to impact the operational landscape, with new compliance requirements being introduced [1].

Core Insights - The implementation of the "Opinions on Promoting and Regulating the Application Development of 'Artificial Intelligence + Healthcare'" by the National Health Commission and other departments marks a significant step towards the commercialization of medical AI and the rapid growth of the industry [1][6] - The policy aims to deepen key applications in eight areas, including AI in grassroots healthcare, clinical diagnosis, patient services, and public health, with a goal of widespread application by 2027 and full coverage by 2030 [1][6] - iFlytek Medical has established itself as a pioneer in the medical AI sector, launching a diverse range of AI products aimed at grassroots healthcare, hospitals, and patients, leveraging its first-mover advantage [2][6] Industry Growth - The Chinese medical AI industry is experiencing rapid growth, with a compound annual growth rate (CAGR) of 33.8% from 2019 to 2023, and an expected CAGR of 43% from 2023 to 2033, potentially reaching a market size of 315.7 billion yuan [5][6] - The "Opinions" are expected to accelerate industry growth by promoting AI applications across various fields, positioning iFlytek Medical to capture a larger market share [6] Technological Advancements - iFlytek Medical has made significant advancements in AI technology, transitioning from voice recognition and natural language processing to large models, achieving a leap in capabilities that surpasses competitors like GPT-5 and DeepSeek V3.2-Exp [3][4] - The upgraded iFlytek Spark Medical model has demonstrated high diagnostic accuracy, achieving 93.1% in outpatient scenarios and matching the performance of senior hospital directors in complex inpatient settings [4] Product Development - iFlytek Medical has developed a comprehensive suite of AI products, including the iMedical Assistant for hospitals and the upgraded iFlytek Xiaoyi app for residents, enhancing diagnostic support and patient engagement [4][6] - The company is focused on building a robust technological foundation and user barriers through continuous R&D investment and product iteration, maintaining its leading position in AI medical technology [6]

Core Insights - The implementation of the "Guidelines for Promoting and Regulating the Application Development of 'Artificial Intelligence + Healthcare'" is set to drive the large-scale commercialization of medical AI and accelerate industry growth over the next five years [1][6] - The medical AI sector in China is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 43% from 2023 to 2033, potentially reaching a market size of 315.7 billion yuan [5][6] Group 1: Policy and Market Dynamics - The "Implementation Opinions" aim to deepen key applications of AI in healthcare, including AI in grassroots applications, clinical diagnosis, patient services, and public health [1] - By 2027, the goal is to establish a range of specialized clinical models and intelligent applications, with widespread use of AI-assisted decision-making in healthcare institutions [1] - The policy is expected to accelerate industry growth, with the initial focus on two major application scenarios contributing significantly to market expansion [6] Group 2: Company Positioning and Innovations - iFlytek Medical has launched a diverse range of AI products targeting grassroots healthcare, hospitals, and patients, establishing a leading position in the medical AI sector [2] - The company has made significant advancements in AI technology, transitioning from voice recognition to large models, and has achieved a leap in capabilities with its Starfire Medical Model [3][4] - iFlytek Medical's AI products now support diagnosis for 2,500 diseases with a first diagnosis accuracy of 98%, showcasing its strong technological foundation [3][4] Group 3: Competitive Landscape and Future Outlook - The company is positioned to capture a larger market share due to its first-mover advantage and robust technological moat, supported by high R&D investment [6] - iFlytek Medical aims to expand its reach globally, leveraging its domestic computing power and open ecosystem strategy to build a new medical AI ecosystem [6] - As the first medical AI large model stock listed in Hong Kong, the company is expected to maintain high growth in the medical AI sector over the next five years, leading to higher valuation premiums [6]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 訊飛醫療科技股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Insights - The "2025 Cyberport Venture Capital Forum" was inaugurated on November 6, focusing on the new landscape of global venture capital driven by artificial intelligence (AI) [1] - Cyberport has added 10 new listed companies this year, including Minglue Technology-W (02718), Cloudwalk (02670), and iFlytek Medical Technology (02506), all of which successfully went public after settling in Cyberport [1] - Two unicorn companies have also joined Cyberport, namely Qiangnao Technology, valued at $1.3 billion, and Langchao Cloud, valued at $2.5 billion, enhancing the local innovation ecosystem in Hong Kong [1] - Despite a challenging global venture capital environment over the past year, Cyberport companies have demonstrated strong fundraising performance, raising nearly 3.4 billion in the period from October 2024 to September 2025, with a cumulative total of 46 billion [1] Company and Industry Summary - Recent significant financing successes among Cyberport companies include KLN (00636), Bowtie, KPay, Kun, Hashkey Group, DigiFT, LeapXpert, and Animoca Brands, indicating a strong focus on AI, blockchain, and digital assets [2] - The successful fundraising cases reflect the capital market's high attention to these sectors and validate Cyberport's effectiveness in promoting the development of AI and Web 3.0 industries [2]